Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Pulse Biosciences Inc - SIC # 3845 - ELECTROMEDICAL AND ELECTROTHERAPEUTIC APPARATUS
Ticker
Exchange
SIC #
Website
Latest Ticker
PLSE
Nasdaq
3845
https://www.pulsebiosciences.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Pulse Biosciences Inc
Pulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2023 Earnings Call Transcript
- Apr 1st, 2024 8:19 pm
Q4 2023 Pulse Biosciences Inc Earnings Call
- Mar 29th, 2024 10:30 am
Pulse Biosciences Inc (PLSE) Reports Increased GAAP Costs and Narrowed Net Loss in 2023
- Mar 28th, 2024 9:51 pm
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results
- Mar 28th, 2024 8:12 pm
Pulse Biosciences Announces Plans to Initiate a Rights Offering
- Mar 28th, 2024 8:10 pm
Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024
- Mar 14th, 2024 8:05 pm
Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System
- Mar 8th, 2024 6:17 pm
Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study
- Feb 14th, 2024 1:00 pm
Companies Like Pulse Biosciences (NASDAQ:PLSE) Are In A Position To Invest In Growth
- Feb 2nd, 2024 2:53 pm
Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium
- Jan 31st, 2024 1:00 pm
Insiders of Pulse Biosciences, Inc. (NASDAQ:PLSE) must be disappointed as stock fell 26% after recent purchases
- Jan 6th, 2024 2:01 pm
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp
- Jan 2nd, 2024 1:00 pm
Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac Catheter
- Dec 20th, 2023 1:00 pm
Executive Chairman of Pulse Biosciences Robert Duggan Buys More Stock
- Dec 3rd, 2023 12:09 pm
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous Electrode
- Nov 21st, 2023 1:00 pm
Chief Strategy Officer of Pulse Biosciences Picks Up 24% More Stock
- Nov 18th, 2023 12:11 pm
Pulse Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference
- Nov 15th, 2023 9:05 pm
Pulse Biosciences, Inc. (NASDAQ:PLSE) Q3 2023 Earnings Call Transcript
- Nov 14th, 2023 5:52 pm
Q3 2023 Pulse Biosciences Inc Earnings Call
- Nov 14th, 2023 7:15 am
Pulse Biosciences Inc (PLSE) Reports Decrease in Q3 Losses and Advances in Cardiac Device ...
- Nov 13th, 2023 4:13 pm
Scroll